Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of KN026 plus docetaxel as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer
CTR20211052Phase 2Active
- Sponsor
- Alphamab Oncology
- Start
- Aug 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab, docetaxel in breast cancer, sponsored by Alphamab Oncology. Started Aug 2021; status: active.
02
Drugs
anbenitamabdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20211052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211052.